Symbols

NTBL(Delisted)

Notable Labs·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NTBL

Notable Labs, Ltd.

A clinical-stage treatment platform company developing predictive precision medicines for cancer patients

Industry

Established Date

01/27/2000

Listing Date

10/01/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.notablelabs.com

Security Type

Common stock

Office address

320 Hatch Drive, Foster City, California, 94404

Business

Introduction

Notable Labs, Ltd., was established in Israel on January 27, 2000. The company is a clinical-stage platform therapy company that develops predictive precision drugs for cancer patients. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable Bio-simulates a cancer treatment designed to predict whether a patient is likely to respond to this particular treatment. Notable's PPMP is designed to identify and select clinically responsive patients before they receive treatment, thereby accelerating the clinical development of this patient population. By continuously advancing and expanding PPMP's coverage in a variety of diseases and expected medical outcomes, Notable aims to become a leader in precision medicine and revolutionize the way patients seek and receive the treatment that best suits them — patient by patient and cancer by cancer. Notable believes that it creates a targeted, risk-reducing licensing strategy that delivers the medical effects and commercial value of a product in a faster, higher, and more likely way than traditional drug development. By changing the standard of historical care, Notable aims to create a huge positive impact for patients and the healthcare community.

Company Financials

EPS

NTBL has released its 2023 Q4 earnings. EPS was reported at -0.43, versus the expected -0.43, meeting expectations. The chart below visualizes how NTBL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

NTBL has released its 2024 Q2 earnings report, with revenue of 2.00K, reflecting a YoY change of NaN%, and net profit of -5.22M, showing a YoY change of -51.94%. The Sankey diagram below clearly presents NTBL's revenue sources and cost distribution.